Which has stronger earnings & valuation, CRVS or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A Telix Pharmaceuticals $803.79M 4.74 -$7.12M N/A N/A

Is CRVS or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% Telix Pharmaceuticals N/A N/A N/A

Which has preferable earnings and valuation, CRVS or CELC?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is CRVS or CELC more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% Celcuity N/A -350.78% -41.54%

Is CRVS or RLAY more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% Relay Therapeutics N/A -42.27% -38.67%

Which has preferable earnings & valuation, VKTX or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is VKTX or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -94.56% -82.75% Corvus Pharmaceuticals N/A -36.15% -33.62%

Corvus Pharmaceuticals (CRVS) Competitors

$10.52 +0.31 (+3.04%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.52 0.00 (-0.05%)

As of 10/9/2026 07:30 PM Eastern

Compare

CRVS vs. TLX, CELC, RLAY, VKTX, and VCYT

Should you buy Corvus Pharmaceuticals stock or one of its competitors? Corvus Pharmaceuticals's main competitors and comparable companies include Telix Pharmaceuticals (TLX), Celcuity (CELC), Relay Therapeutics (RLAY), Viking Therapeutics (VKTX), and Veracyte (VCYT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Corvus Pharmaceuticals compare to Telix Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Telix Pharmaceuticals' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Telix Pharmaceuticals	N/A	N/A	N/A

Corvus Pharmaceuticals presently has a consensus target price of $33.33, suggesting a potential upside of 216.86%. Telix Pharmaceuticals has a consensus target price of $20.50, suggesting a potential upside of 82.87%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Corvus Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Corvus Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Telix Pharmaceuticals had 10 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 11 mentions for Telix Pharmaceuticals and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 0.00 beat Telix Pharmaceuticals' score of -0.06 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corvus Pharmaceuticals	Neutral
Telix Pharmaceuticals	Neutral

Telix Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Telix Pharmaceuticals	$803.79M	4.74	-$7.12M	N/A	N/A

Summary

Corvus Pharmaceuticals beats Telix Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Celcuity?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Corvus Pharmaceuticals' return on equity of -36.15% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Celcuity	N/A	-350.78%	-41.54%

Corvus Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Corvus Pharmaceuticals presently has a consensus price target of $33.33, suggesting a potential upside of 216.86%. Celcuity has a consensus price target of $154.25, suggesting a potential upside of 127.04%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Corvus Pharmaceuticals is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Celcuity had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 5 mentions for Celcuity and 1 mentions for Corvus Pharmaceuticals. Celcuity's average media sentiment score of 0.04 beat Corvus Pharmaceuticals' score of 0.00 indicating that Celcuity is being referred to more favorably in the news media.

Company	Overall Sentiment
Corvus Pharmaceuticals	Neutral
Celcuity	Neutral

Summary

Corvus Pharmaceuticals beats Celcuity on 9 of the 14 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Relay Therapeutics?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Relay Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Relay Therapeutics	$15.35M	255.26	-$276.48M	-$1.57	N/A

Corvus Pharmaceuticals presently has a consensus price target of $33.33, indicating a potential upside of 216.86%. Relay Therapeutics has a consensus price target of $25.92, indicating a potential upside of 44.95%. Given Corvus Pharmaceuticals' higher probable upside, research analysts clearly believe Corvus Pharmaceuticals is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Corvus Pharmaceuticals' return on equity of -36.15% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Relay Therapeutics	N/A	-42.27%	-38.67%

Corvus Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market.

In the previous week, Relay Therapeutics had 10 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 11 mentions for Relay Therapeutics and 1 mentions for Corvus Pharmaceuticals. Relay Therapeutics' average media sentiment score of 0.44 beat Corvus Pharmaceuticals' score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Corvus Pharmaceuticals	Neutral
Relay Therapeutics	Neutral

Summary

Relay Therapeutics beats Corvus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Corvus Pharmaceuticals' return on equity of -36.15% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Viking Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Viking Therapeutics presently has a consensus price target of $99.44, suggesting a potential upside of 248.81%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 216.86%. Given Viking Therapeutics' higher probable upside, equities analysts plainly believe Viking Therapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Viking Therapeutics had 10 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 11 mentions for Viking Therapeutics and 1 mentions for Corvus Pharmaceuticals. Viking Therapeutics' average media sentiment score of 0.54 beat Corvus Pharmaceuticals' score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Viking Therapeutics	Positive
Corvus Pharmaceuticals	Neutral

Summary

Corvus Pharmaceuticals beats Viking Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Veracyte has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

Veracyte has a net margin of 20.37% compared to Corvus Pharmaceuticals' net margin of 0.00%. Veracyte's return on equity of 9.26% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Veracyte has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.03	$66.35M	$1.41	32.08
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Veracyte currently has a consensus target price of $55.78, suggesting a potential upside of 23.32%. Corvus Pharmaceuticals has a consensus target price of $33.33, suggesting a potential upside of 216.86%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Veracyte had 5 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Veracyte and 1 mentions for Corvus Pharmaceuticals. Veracyte's average media sentiment score of 0.37 beat Corvus Pharmaceuticals' score of 0.00 indicating that Veracyte is being referred to more favorably in the media.

Company	Overall Sentiment
Veracyte	Neutral
Corvus Pharmaceuticals	Neutral

Summary

Veracyte beats Corvus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get Corvus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVS vs. The Competition

Export

Metric	Corvus Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$858.88M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-17.25	13.42	274.15	26.16
Price / Sales	N/A	1,234.38	635.98	112.53
Price / Cash	80.55	116.56	76.38	53.09
Price / Book	14.41	17.17	11.21	6.34
Net Income	-$15.28M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-3.49%	-1.33%	-0.90%	-1.41%
1 Month Performance	-18.70%	-8.44%	-4.44%	-3.48%
1 Year Performance	51.80%	14.02%	6.96%	1.16%

Corvus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVS Corvus Pharmaceuticals	1.6275 of 5 stars	$10.52 +3.0%	$33.33 +216.9%	+45.1%	$858.88M	N/A	N/A	37
TLX Telix Pharmaceuticals	4.3613 of 5 stars	$11.34 -2.4%	$20.50 +80.8%	+11.1%	$3.95B	$803.79M	N/A	1,184
CELC Celcuity	2.9613 of 5 stars	$77.38 -2.8%	$154.75 +100.0%	+37.3%	$3.90B	N/A	N/A	155
RLAY Relay Therapeutics	2.5229 of 5 stars	$18.36 +3.8%	$25.92 +41.2%	+163.7%	$3.88B	$15.35M	N/A	192	Trending News Insider Trade Gap Down
VKTX Viking Therapeutics	3.7557 of 5 stars	$31.81 -3.7%	$99.67 +213.3%	-18.5%	$3.85B	N/A	N/A	65	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVS) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. TLX, CELC, RLAY, VKTX, and VCYT

How does Corvus Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Corvus Pharmaceuticals compare to Celcuity?

Summary

How does Corvus Pharmaceuticals compare to Relay Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Viking Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Veracyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. TLX, CELC, RLAY, VKTX, and VCYT

How does Corvus Pharmaceuticals compare to Telix Pharmaceuticals?

Is CRVS or TLX more profitable?

Do analysts prefer CRVS or TLX?

Which has more volatility & risk, CRVS or TLX?

Do insiders and institutionals have more ownership in CRVS or TLX?

Does the media prefer CRVS or TLX?

Which has stronger earnings & valuation, CRVS or TLX?

Summary

How does Corvus Pharmaceuticals compare to Celcuity?

Do insiders and institutionals have more ownership in CRVS or CELC?

Which has preferable earnings and valuation, CRVS or CELC?

Is CRVS or CELC more profitable?

Which has more volatility & risk, CRVS or CELC?

Do analysts prefer CRVS or CELC?

Does the media favor CRVS or CELC?

Summary

How does Corvus Pharmaceuticals compare to Relay Therapeutics?

Which has preferable valuation and earnings, CRVS or RLAY?

Do analysts prefer CRVS or RLAY?

Do institutionals & insiders believe in CRVS or RLAY?

Is CRVS or RLAY more profitable?

Which has more risk & volatility, CRVS or RLAY?

Does the media prefer CRVS or RLAY?

Summary

How does Corvus Pharmaceuticals compare to Viking Therapeutics?

Which has preferable earnings & valuation, VKTX or CRVS?

Do insiders & institutionals hold more shares of VKTX or CRVS?

Is VKTX or CRVS more profitable?

Which has more volatility and risk, VKTX or CRVS?

Do analysts rate VKTX or CRVS?

Does the media prefer VKTX or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Veracyte?

Which has more volatility & risk, VCYT or CRVS?

Is VCYT or CRVS more profitable?

Which has better valuation and earnings, VCYT or CRVS?

Do insiders and institutionals hold more shares of VCYT or CRVS?

Do analysts recommend VCYT or CRVS?

Does the media favor VCYT or CRVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools